Vasculitis Pediatric Research and Clinical Trials

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Research & Innovation

As a national referral center for Kawasaki disease, Children’s Hospital Boston is on the forefront of treatments for this type of vasculitis. Most of the current therapies for Kawasaki, in fact, were either initiated or validated here. But advances in diagnosis are equally important: Without timely treatment, Kawasaki may inflame the coronary arteries and lead to potentially life-threatening heart problems. Children’s researchers are now working to identify proteins in urine that may act as a biomarker -- or red flag -- for whether a child has Kawasaki, and allow treatment to begin as soon as possible.

Through clinical trials and research projects, Children’s is also helping to pioneer the use of biologics -- protein-based drugs made from living cells -- for a number of pediatric diseases, including vasculitis. Most recently, our rheumatologists examined a class of biologics called tumor necrosis factor (TNF) blockers as a treatment for Takayasu arteritis. In a study of Children’s patients, they found that TNF blockers worked reliably with other medications to help sustain remission in Takayasu patients.

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close